Will you use ovarian function suppression in lieu of chemotherapy in premenopausal patients with pN1 ER+ HER2- breast CA with OncoType RS <25?
Knowing the differential effect seen with menopausal status in RxPONDER, would you avoid chemotherapy or still offer chemotherapy, given that only 15.9% of premenopausal patients in the endocrine therapy arm were given OFS?
Community PollStarted
What adjuvant strategy will you offer for premenopausal patients with pN1 ER+ HER2- breast CA with OncoType RS <25?
48 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Private Practice and Digital Health
Answered on
Most certainly. The difference between chemotherapy effect in postmenopausal vs. premenopausal women with ER+ breast cancer is not primarily due to a difference in disease biology. It is due to the endocrine effect of chemotherapy in premenopausal women and the lack of that effect in postmenopausal ...
Join for free or sign in to see the full answer